Pfizer sues Johnson & Johnson for alleged monopolistic behaviour
In a move the company is touting as an attempt to get lower-cost biosimilar medicines into the hands of patients, Pfizer has sued Johnson & Johnson for alleged anticompetitive behaviour in the growing biologics market.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10